ESTRO Brachytherapy for Prostate Cancer 2018

In contrast to some previous studies, dosimetric outcomes did not correlate with biochemical recurrence in the first 1,006 patients treated with 125I prostate brachytherapy at the British Columbia Cancer Agency.

International Journal of Radiation Oncology, Biology, Physics, 2009, Vol.73(5), pp.1432-1438